Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 10, 2025 08:00 ET | Source: Inozyme Pharma Inc.

Inozyme Pharma Announces Positive Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency and Key Program Updates

Inozyme Pharma Announces Positive Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency and Key Program Updates
August 06, 2024 08:30 ET | Source: Inozyme Pharma Inc.

Inozyme Pharma Reports Second Quarter 2024 Financial Results and Provides Business Highlights

Inozyme reported financial results for the second quarter ended June 30, 2024, and provided business highlights.
May 07, 2024 08:30 ET | Source: Inozyme Pharma Inc.

Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights

Inozyme reported financial results for the first quarter ended March 31, 2024 and provided business highlights.
March 26, 2024 08:30 ET | Source: Inozyme Pharma Inc.

Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024

Inozyme announced that it will host a conference call and webcast on Monday, Apr. 8, 2024 at 8:00 a.m. ET.
February 04, 2021 06:00 ET | Source: Inozyme Pharma Inc.

Inozyme Pharma Appoints Deborah Wenkert, M.D., as Senior Vice President and Chief Medical Officer

BOSTON, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases of abnormal...
January 04, 2021 06:00 ET | Source: Inozyme Pharma Inc.

Inozyme Pharma Announces Authorization to Proceed in U.S. and U.K. with Phase 1/2 Clinical Trial of INZ-701 for the Treatment of ENPP1 Deficiency

– U.S. Food and Drug Administration cleared Investigational New Drug Application – – United Kingdom Medicines and Healthcare Products Regulatory Agency authorized Clinical Trial Application – –...